FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361949394> ?p ?o ?g. }

• W4361949394 abstract "<div>Abstract<p><b>Purpose:</b> Interleukin-6 (IL-6) induces tumor growth, invasion, metastasis, and angiogenesis. Siltuximab (CNTO 328) is a chimeric, murine-human monoclonal antibody that specifically binds human IL-6 with high affinity. C-reactive protein (CRP) can be a pharmacodynamic (PD) marker of IL-6 bioactivity. Reductions in CRP may correlate with clinical activity and IL-6 bioactivity.</p><p><b>Experimental Design:</b> Starting-dose selection for this study was based on a previous siltuximab study in multiple myeloma patients. Pharmacokinetic (PK)/PD modeling explored the relationship between siltuximab PK and CRP suppression following i.v. siltuximab infusion in a three-part phase I/II study in 68 metastatic renal cell carcinoma patients. Modeling results were then used to simulate and determine which siltuximab dosage regimens would maintain CRP suppression below the lower limit of quantification (4 mg/L). Siltuximab was given at 1, 3, 6, or 12 mg/kg at weeks 1 and 4 and then every 2 weeks for 2 cycles in part 1; at 3 or 6 mg/kg every 3 weeks for 4 cycles in part 2; and at 6 mg/kg every 2 weeks for 6 cycles in part 3.</p><p><b>Results:</b> A two-compartment PK model adequately described the serum siltuximab concentration-time data. An inhibitory indirect response PD model examined the relationship between siltuximab concentrations and CRP suppression. PD parameter estimates seemed reliable and physiologically relevant. Simulations showed that 6 mg/kg siltuximab every 2 weeks or 9 mg/kg every 3 weeks would reduce serum CRP to below 4 mg/L.</p><p><b>Conclusions:</b> Using a stepwise design, PK/PD modeling was used to select the dose levels in this study. Furthermore, PK/PD modeling results were used to help select doses to be used in future siltuximab clinical development. Clin Cancer Res; 16(5); 1652–61</p></div>" @default.
• W4361949394 created "2023-04-05" @default.
• W4361949394 creator A5020318596 @default.
• W4361949394 creator A5033437574 @default.
• W4361949394 creator A5069409328 @default.
• W4361949394 creator A5076610847 @default.
• W4361949394 creator A5086588343 @default.
• W4361949394 date "2023-03-31" @default.
• W4361949394 modified "2023-09-26" @default.
• W4361949394 title "Data from Pharmacokinetic and Pharmacodynamic Modeling of an Anti–Interleukin-6 Chimeric Monoclonal Antibody (Siltuximab) in Patients with Metastatic Renal Cell Carcinoma" @default.
• W4361949394 doi "https://doi.org/10.1158/1078-0432.c.6518742.v1" @default.
• W4361949394 hasPublicationYear "2023" @default.
• W4361949394 type Work @default.
• W4361949394 citedByCount "0" @default.
• W4361949394 crossrefType "posted-content" @default.
• W4361949394 hasAuthorship W4361949394A5020318596 @default.
• W4361949394 hasAuthorship W4361949394A5033437574 @default.
• W4361949394 hasAuthorship W4361949394A5069409328 @default.
• W4361949394 hasAuthorship W4361949394A5076610847 @default.
• W4361949394 hasAuthorship W4361949394A5086588343 @default.
• W4361949394 hasConcept C111113717 @default.
• W4361949394 hasConcept C112705442 @default.
• W4361949394 hasConcept C126322002 @default.
• W4361949394 hasConcept C159654299 @default.
• W4361949394 hasConcept C203014093 @default.
• W4361949394 hasConcept C2776364478 @default.
• W4361949394 hasConcept C2777472916 @default.
• W4361949394 hasConcept C542903549 @default.
• W4361949394 hasConcept C71924100 @default.
• W4361949394 hasConcept C98274493 @default.
• W4361949394 hasConceptScore W4361949394C111113717 @default.
• W4361949394 hasConceptScore W4361949394C112705442 @default.
• W4361949394 hasConceptScore W4361949394C126322002 @default.
• W4361949394 hasConceptScore W4361949394C159654299 @default.
• W4361949394 hasConceptScore W4361949394C203014093 @default.
• W4361949394 hasConceptScore W4361949394C2776364478 @default.
• W4361949394 hasConceptScore W4361949394C2777472916 @default.
• W4361949394 hasConceptScore W4361949394C542903549 @default.
• W4361949394 hasConceptScore W4361949394C71924100 @default.
• W4361949394 hasConceptScore W4361949394C98274493 @default.
• W4361949394 hasLocation W43619493941 @default.
• W4361949394 hasOpenAccess W4361949394 @default.
• W4361949394 hasPrimaryLocation W43619493941 @default.
• W4361949394 hasRelatedWork W1758514097 @default.
• W4361949394 hasRelatedWork W1997101420 @default.
• W4361949394 hasRelatedWork W2002058825 @default.
• W4361949394 hasRelatedWork W2010116591 @default.
• W4361949394 hasRelatedWork W2090099591 @default.
• W4361949394 hasRelatedWork W2108417615 @default.
• W4361949394 hasRelatedWork W2227061539 @default.
• W4361949394 hasRelatedWork W2410816841 @default.
• W4361949394 hasRelatedWork W2594910449 @default.
• W4361949394 hasRelatedWork W2992709639 @default.
• W4361949394 isParatext "false" @default.
• W4361949394 isRetracted "false" @default.
• W4361949394 workType "article" @default.